tirzepatide cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

29.33

★★★★☆4.8 (126)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

25.47

★★★★★4.9 (98)

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

20.98

★★★★★5.0 (157)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

29.35

★★★★★4.7 (84)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

28.30

★★★★★4.9 (203)

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. “Cardiologists now have an ever-expanding

27.06

★★★★★5.0 (176)

Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

26.51

★★★★★4.8 (132)